Volume 21, Number 8—August 2015
Dispatch
Rabies Postexposure Prophylaxis for Travelers Injured by Nonhuman Primates, Marseille, France, 2001–2014
Agathe Blaise, Philippe Parola, Philippe Brouqui, and Philippe Gautret
Table 1
Demographic, vaccination status, place of exposure, and travel characteristics of 135 persons injured by nonhuman primates requiring rabies postexposure prophylaxis, Marseilles, France, 2001–2014
| Characteristics | No. (%) |
|---|---|
| Female sex | 70 (51.9) |
| Age group, years | |
| 0–15 | 28 (20.7) |
| 16–39 | 71 (52.6) |
| 40–59 | 27 (20.0) |
| 60 and over | 9 (6.7) |
| Preexposure vaccination against rabies | 2 (1.5) |
| Place of exposure | |
| France | 15 (11.1) |
| Thailand | 48 (35.7) |
| Indonesia | 25 (18.5) |
| Other countries in Asia* | 14 (10.4) |
| North Africa† | 13 (9.6) |
| Sub-Saharan Africa‡ | 11 (8.1) |
| Central and South America and Caribbean§ | 6 (4.4) |
| Spain/Rock of Gibraltar | 3 (2.2) |
| Reason for travel, n = 120 | |
| Tourism | 99 (82.5) |
| Other¶ | 6 (5.0) |
| Not documented | 15 (12.5) |
| Days of travel duration, n = 119# | |
| 0–7 | 6 (5.0) |
| 8–14 | 21(17.6) |
| 15–21 | 43 (36.2) |
| 21–28 | 19 (16.0) |
| >29 | 14 (11.8) |
| Not documented | 16 (13.4) |
| Days between first date of travel and exposure, n = 119# | |
| 0–7 | 41 (34.5) |
| 8–14 | 33 (27.6) |
| 15–21 | 17 (14.3) |
| >22 d | 4 (3.4) |
| Not documented | 24 (20.2) |
*Vietnam (5), India (4) Cambodia (3), Myanmar (1), Sri-Lanka (1).
†Morocco (10), Algeria (3).
‡Madagascar (4), Kenya (4), Botswana (1), Cameroon (1), Central African Republic (1).
§Brazil (2), Anguilla (1), Dominican Republic (1), Mexico (1), Peru (1).
¶Persons, or their descendants, who have immigrated to Marseille from another country who were exposed while visiting friends and relatives in their country of origin (3), expatriate (1), humanitarian worker (1), and student (1).
#Expatriate traveler was excluded.
Page created: July 15, 2015
Page updated: July 15, 2015
Page reviewed: July 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.